Premium
DHPLC Analysis of patients with Nevoid Basal Cell Carcinoma Syndrome reveals novel PTCH missense mutations in the sterol‐sensing domain
Author(s) -
Marsh A.,
Wicking C.,
Wainwright B.,
ChenevixTrench G.
Publication year - 2005
Publication title -
human mutation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.981
H-Index - 162
eISSN - 1098-1004
pISSN - 1059-7794
DOI - 10.1002/humu.9365
Subject(s) - nevoid basal cell carcinoma syndrome , missense mutation , biology , genetics , denaturing high performance liquid chromatography , mutation , exon , basal cell carcinoma , indel , microbiology and biotechnology , cancer research , gene , pathology , basal cell , medicine , genotype , single nucleotide polymorphism
Nevoid Basal Cell Carcinoma Syndrome (NBCCS) is an autosomal dominant disorder characterised by multiple basal cell carcinomas, palmar and plantar pitting, odontogenic keratocysts of the jaws and bilamellar calcification of the falx. Mutations in the PTCH gene are responsible for NBCCS but most studies have found mutations in less than half of the cases tested. We used denaturing high performance liquid chromatography (DHPLC) to screen for PTCH mutations in 28 NBCCS cases, most of whom had been previously evaluated by single stranded conformation polymorphism analysis but found to be negative. Protein truncating (n=10) and missense or indel (n=4) mutations were found in 14/28 (50%) cases and one additional case carried an unclassified variant, c.2777G>C. Thirteen of the variants were novel. The mutation frequency was similar in inherited and de novo cases. Three of the missense and indel mutations were in the sterol‐sensing domain, and one was in the sixth transmembrane domain. © 2005 Wiley‐Liss, Inc.